Black Rock Inc. Mi Nk Therapeutics, Inc. Transaction History
Black Rock Inc.
- $4.35 Trillion
- Q2 2024
A detailed history of Black Rock Inc. transactions in Mi Nk Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 87,196 shares of INKT stock, worth $59,293. This represents 0.0% of its overall portfolio holdings.
Number of Shares
87,196
Previous 76,148
14.51%
Holding current value
$59,293
Previous $69,000
18.84%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding INKT
# of Institutions
29Shares Held
848KCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA234KShares$159,2430.0% of portfolio
-
Longbow Finance Sa Lutry, V8167KShares$113,3320.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny107KShares$72,5470.0% of portfolio
-
Geode Capital Management, LLC Boston, MA98KShares$66,6270.0% of portfolio
-
High Tower Advisors, LLC Chicago, IL51.7KShares$35,1750.0% of portfolio
About MiNK Therapeutics, Inc.
- Ticker INKT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 33,775,100
- Market Cap $23M
- Description
- MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy...